Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979885 · ClinicalTrials.gov registry record · NA
Financial Incentives for Smoking Treatment II
A NA study, sponsored by University of California, Los Angeles.
- Active
- Registry status
- NA
- Development phase
- 1,058
- Enrollment target
NCT03979885: Active NA study, sponsored by University of California, Los Angeles.
NCT03979885 is a NA study that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 1,058 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03979885, a NA study, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,058 participants
- Enrollment target
Study Summary
Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.
Primary Outcome
Assessed by self-report questionnaire, and biochemically verified by salivary cotinine
Interventions
- BEHAVIORAL Smoking cessation counseling (Quitline)
- BEHAVIORAL Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
- BEHAVIORAL Financial incentives for smoking cessation
- BEHAVIORAL Financial incentives for use of evidence-based smoking cessation therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,058 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What the registry record for NCT03979885 still lists
NCT03979885 is an interventional study that assigns participants to a tested intervention. Its 1,058 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 4 interventions - of which Smoking cessation counseling (Quitline) is the first listed.
NCT03979885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03979885 about?
NCT03979885 is a clinical study titled "Financial Incentives for Smoking Treatment II". Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretica...
What is the current status of trial NCT03979885?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,058 participants. The study started on 2020-01-06. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT03979885?
The interventions under investigation include: Smoking cessation counseling (Quitline) (BEHAVIORAL), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy) (BEHAVIORAL), Financial incentives for smoking cessation (BEHAVIORAL), Financial incentives for use of evidence-based smoking cessation therapies (BEHAVIORAL).
Who is sponsoring clinical trial NCT03979885?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03979885's enrollment target sits among peer trials
1,058 98th of 2000 higher than 1,902 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI